Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04504383 · ClinicalTrials.gov registry record · Phase 2
PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)
A Phase 2 study, sponsored by Protagonist Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 169
- Enrollment target
NCT04504383 is a Phase 2 study that has completed, run by Protagonist Therapeutics. The registered enrollment target is 169 participants.
The verdict
NCT04504383, a Phase 2 study, has completed, sponsored by Protagonist Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 169 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety, tolerability, and clinical efficacy of PN-943 450 mg twice daily \[BID\] and PN-943 150 mg BID, compared with placebo BID, in subjects with moderate to severe active Ulcerative Colitis (UC).
Interventions
- DRUG Placebo
- DRUG PN-943
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2020-08-05 |
| Est. Completion | 2023-02-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04504383
The ClinicalTrials.gov registry entry for NCT04504383 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 169 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Protagonist Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04504383 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04504383 about?
NCT04504383 is a clinical study titled "PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)". The purpose of the study is to evaluate the safety, tolerability, and clinical efficacy of PN-943 450 mg twice daily \[BID\] and PN-943 150 mg BID, compared with placebo BID, in subjects with moderate to severe active Ulcerative Colitis (UC).
What is the current status of trial NCT04504383?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 169 participants. The study started on 2020-08-05. Estimated completion is 2023-02-16.
What interventions are being tested in trial NCT04504383?
The interventions under investigation include: Placebo (DRUG), PN-943 (DRUG).
Who is sponsoring clinical trial NCT04504383?
This trial is sponsored by Protagonist Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.